Circassia raises $21,800,000

Circassia Ltd., a specialty biopharmaceutical company focused on controlling immune system responses, announced today that it has successfully raised GBP11 million ($21.8 million) in an oversubscribed second round funding.  Circassia’s lead products target allergies  tilising the company’s proprietary T-cell epitope desensitization technology, which was originally developed at Imperial College London. The company is also developing its ToleroTrans organ anti-rejection technology, which uses a similar approach to down-regulate immune responses in transplant patients. Circassia has a number of ongoing development programmes, with the most advanced against cat dander allergy having successfully completed a phase II clinical trial.